No­var­tis' Tafin­lar/Mekin­ist com­bo scores new in­di­ca­tion in pe­di­atric brain can­cer

No­var­tis’ Tafin­lar (dabrafenib) and Mekin­ist (tram­e­tinib) com­bo has been ap­proved for an­oth­er in­di­ca­tion by the FDA — this time for treat­ment of low-grade glioma with a BRAF V600E mu­ta­tion in kids aged 1 year and up.

This marks the sixth ap­proval for the com­bi­na­tion. It’s al­ready ap­proved for use in mul­ti­ple BRAF V600E sol­id tu­mors, in­clud­ing melanoma, thy­roid can­cer and lung can­cer.

Liq­uid for­mu­la­tions for both drugs were al­so ap­proved by the FDA, which No­var­tis said is the first time a BRAF/MEK in­hibitor has been de­vel­oped in a for­mu­la­tion suit­able for pa­tients as young as one.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.